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ABSTRACT
Objective Hepatocellular carcinoma (HCC) is a prevalent 
and aggressive cancer usually arising on a background 
of chronic liver injury involving inflammatory and hepatic 
regenerative processes. The triggering receptor expressed 
on myeloid cells 2 (TREM-2) is predominantly expressed in 
hepatic non- parenchymal cells and inhibits Toll- like receptor 
signalling, protecting the liver from various hepatotoxic 
injuries, yet its role in liver cancer is poorly defined. Here, 
we investigated the impact of TREM-2 on liver regeneration 
and hepatocarcinogenesis.
Design TREM-2 expression was analysed in liver tissues 
of two independent cohorts of patients with HCC and 
compared with control liver samples. Experimental HCC 
and liver regeneration models in wild type and Trem-2-/-
 mice, and in vitro studies with hepatic stellate cells (HSCs) 
and HCC spheroids were conducted.
Results TREM-2 expression was upregulated in human 
HCC tissue, in mouse models of liver regeneration and 
HCC. Trem-2-/- mice developed more liver tumours 
irrespective of size after diethylnitrosamine (DEN) 
administration, displayed exacerbated liver damage, 
inflammation, oxidative stress and hepatocyte proliferation. 
Administering an antioxidant diet blocked DEN- induced 
hepatocarcinogenesis in both genotypes. Similarly, 
Trem-2-/- animals developed more and larger tumours in 
fibrosis- associated HCC models. Trem-2-/- livers showed 
increased hepatocyte proliferation and inflammation after 
partial hepatectomy. Conditioned media from human HSCs 
overexpressing TREM-2 inhibited human HCC spheroid 
growth in vitro through attenuated Wnt ligand secretion.
Conclusion TREM-2 plays a protective role in 
hepatocarcinogenesis via different pleiotropic effects, 
suggesting that TREM-2 agonism should be investigated 
as it might beneficially impact HCC pathogenesis in a 
multifactorial manner.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most 
common cancer and the third leading cause of 
cancer- related mortality worldwide. HCC usually 
arises on the background of chronic liver injury and 
inflammation, mainly triggered by infectious agents 
(eg, hepatitis B and C virus), alcohol abuse and/or 
excessive hepatocellular fat accumulation.1 During 
the past few years, it has become evident that innate 
immunity plays a critical role in the development 
and progression of several liver diseases, including 
HCC.2
The triggering receptor expressed on myeloid 
cells 2 (TREM-2) is an anti- inflammatory receptor 
that negatively regulates toll- like receptor (TLR)- 
mediated inflammatory responses, whereas the 
proinflammatory receptor TREM-1 augments 
TLR- induced inflammation.3 4 Both receptors 
signal through the immunoreceptor tyrosine- based 
Significance of this study
What is already known on this subject?
 ► Hepatocellular carcinoma (HCC) is a prevalent 
cancer and its pathogenesis is a multistep 
process involving the progressive accumulation 
of molecular alterations. HCC usually arises on 
a background of chronic liver injury involving 
inflammatory and hepatic regenerative 
processes.
 ► Increasing evidence suggests the gut–liver axis 
and innate immunity play a critical role in the 
development and progression of several liver 
diseases, including HCC. Fine- tuning of Toll- like 
receptor (TLR)- driven inflammation during liver 
cancer is key.
 ► The triggering receptor expressed on myeloid 
cells 2 (TREM-2) negatively regulates TLR- 
mediated inflammatory responses.
 ► TREM-2 is expressed on non- parenchymal liver 
cells and is upregulated during diverse forms 
of liver injury in humans and mice. TREM-2 
promotes the resolution of inflammation during 
diverse types of hepatic injury, ultimately 
preventing parenchymal cell death.
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activation motif of the adaptor protein DAP-12.5 The ligand(s) 
for TREM-2 are unknown although numerous are proposed, 
ranging from various anionic molecules; phospholipids, proteo-
glycans to apolipoproteins and heat shock proteins.6–9 TREM-2 
has been mainly studied in the brain, where its deficiency in 
microglia is associated with several neurodegenerative disorders, 
including Alzheimer’s disease.10–12 The role of TREM-2 in cancer 
is poorly understood, although several studies suggest that high 
TREM-2 expression correlates with worsened outcome during 
various cancers including gastric, glioma and renal cell carci-
noma.13–15 On the other hand, in the liver, we recently described 
that TREM-2 is predominantly expressed in non- parenchymal 
cells (ie, Kupffer cells (KCs) and hepatic stellate cells (HSCs)), 
where it serves to attenuate TLR4- mediated cytokine produc-
tion.16 Notably, herein we could show that mice deficient for 
Trem-2 displayed increased liver damage and inflammation 
post- acetaminophen and acute or chronic carbon tetrachloride 
(CCl4) administration. Given the crucial role of innate immunity 
in HCC, we hypothesised that TREM-2 could play a protective 
role in its development and progression.
MATERIALS AND METHODS
Patients
TREM-2 expression was determined in 366 HCC and 49 non- 
tumour tissues surrounding HCC from the RNAseq data of 
the cancer genome atlas (TCGA) (‘TCGA cohort’) in Reads 
per Kilobase Million. Level 3 RNA- seq data generated by 
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 
(TCGA- LIHC) consortium were downloaded from the National 
Cancer Institute Genomic Data Commons (https:// gdc. cancer. 
gov/).17 Moreover, 35 HCC human biopsies of different etiolo-
gies and 21 control liver tissues (from non- neoplastic liver tissue 
of patients with colorectal hepatic metastasis) were obtained 
from the Biobank of Donostia University Hospital (‘San Sebas-
tian cohort’) for the analysis of TREM-2 expression and several 
pro- fibrotic and pro- inflammatory genes by quantitative poly-
merase chain reaction (qPCR). Patient information is detailed in 
online supplementary table 1. Samples and clinicopathological 
information were obtained from the Basque Biobank. Single- cell 
transcriptome profiling of human HCC tumour biospecimens 
from nine HCC tumours was downloaded from Gene Expres-
sion Ominbus (GSE125449). Patient specific characteristics of 
this data set are previously described and all patients provided 
informed consent.18 Briefly, HCC tumour samples of various 
aetiologies were obtained by resection or needle biopsy from five 
males (ages 61–77) and four females (ages 41–64), with several 
patients receiving immunotherapy.18
Animal models
Wild type (WT) C57BL/6 and Trem-2-/- mice backcrossed onto 
a>98% C57BL/6 background were generated as previously 
described.3 Mice were bred and housed at the animal facility 
of the Biodonostia Health Research Institute in the same room 
under specific pathogen free conditions with microisolator tops. 
All experiments were performed under approval of the Animal 
Experimentation Ethics Committee of the Institution.
HCC was induced in WT and Trem-2-/- male mice by the 
administration of a single intraperitoneal injection of the hepa-
tocarcinogen diethylnitrosamine (DEN; Sigma- Aldrich) (30 
mg/kg of DEN dissolved in 0.9% saline) at 15 days of age. Mice 
were humanely killed at 30 or 40 weeks post- injection. To eval-
uate the role of reactive oxygen species (ROS), 15 weeks after 
DEN administration, both genotypes were fed a diet supple-
mented with 0.7% w/w of the antioxidant butylated hydroxy-
anisole (BHA; Sigma- Aldrich) for another 15 weeks prior to 
sacrifice. To evaluate effects of acute DEN treatment on the 
liver, 8 week- old male WT and Trem-2-/- mice were injected 
with 100 mg/kg DEN and sacrificed 6, 24 and 72 hours post- 
injection. Regenerative responses were evaluated in 8 week- old 
male WT and Trem-2-/- mice using partial hepatectomy (PHx 
~70%), as previously described.19 To stain proliferating 
hepatocytes, mice were intraperitoneally injected with 150 
mg/kg of 5′- bromo-2′- deoxyuridine (BRDU; Sigma- Aldrich) 
2 hours before humane killing. Fibrosis- associated HCC was 
induced in WT and Trem-2-/- male mice by combining chronic 
DEN administration (30 mg/kg, intraperitoneal, 15 days post- 
partum) with 10 weekly injections (one injection per week) 
of CCl4 at 2 µL/g body weight (CCl4/olive oil 1:3 (vol:vol)), 
starting at 4 weeks of age (2 weeks after DEN injection). Mice 
were humanely killed 30 weeks after DEN injection. As a 
second approach for fibrosis- associated HCC, 8 week- old WT 
and Trem-2-/- male mice were administered 0.03% (w/v) thioac-
etamide (TAA) (Sigma- Aldrich) in drinking water for 40 weeks. 
Tumour volume in animals was calculated using the formula Tv 
= (W(2) × L)/2.20
Gain- of- function experiments were performed overexpressing 
TREM-2 in 8- week- old WT C57BL/6 mice by intravenous 
tail vein injection with control (AAV8- CMV- eGFP; VECTOR 
Biosystems) or Trem-2 overexpressing adeno- associated viruses 
(AAV8- CMV- TREM-2- IRES- eGFP; VECTOR Biosystems) 
(1×1011 pfu) dissolved in 0.9% saline. Next, 72 hours after AAV 
Significance of this study
What are the new findings?
 ► TREM-2 expression is upregulated in human HCC tissue, in 
mouse models of liver regeneration and HCC.
 ► In human HCC tumours, TREM-2 is expressed in infiltrating 
monocyte derived macrophages.
 ► Trem-2-/- mice developed increased number of liver tumours 
after diethylnitrosamine (DEN) administration, displayed 
exacerbated liver damage, inflammation, oxidative stress and 
hepatocyte proliferation.
 ► Liver cancer in Trem-2-/- mice is associated with elevated 
reactive oxygen species levels and the administration of an 
antioxidant diet blocked DEN- induced DNA damage and 
hepatocarcinogenesis in these animals.
 ► In fibrosis- associated HCC models, Trem-2-/- mice also 
exhibited elevated tumour burden and less fibrosis.
 ► Trem-2-/- livers exhibited increased hepatocyte proliferation 
and inflammation after partial hepatectomy (PHx). 
The suppressive effects of this receptor on hepatocyte 
proliferation were linked to its effects on early inflammatory 
events post- PHx.
 ► In line with TREM-2 effects on inflammation and 
proliferation, conditioned media from human hepatic stellate 
cells overexpressing TREM-2 inhibited human HCC spheroid 
growth in vitro.
How might it impact on clinical practice in the foreseeable 
future?
 ► While strategies aiming to activate TREM-2 in the context of 
HCC are warranted, as TREM-2 agonism might beneficially 
impact tumour burden in a pleiotropic manner, they will 
require a detailed evaluation for potential profibrotic 
side- effects.
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injection, mice were injected with DEN (100 mg/kg) and sacri-
ficed 72 hours post- DEN.
Statistical analysis
Statistical analysis was performed with GraphPad Prism V.6.00 
software (GraphPad Software, San Diego, CA). Data are 
expressed as mean ± standard error of the mean (SEM). For 
comparisons between two groups, parametric Student’s t- test or 
non- parametric Mann- Whitney test were used. When more than 
two groups were compared, one- way analysis of variance with 
Tukey’s posthoc test or Kruskal- Wallis test followed by Dunn’s 
multiple comparison test were used. For correlation analysis, 
non- parametric Spearman’s correlation test was used. Statisti-
cally significant differences are represented in figures as *, **, 
***, **** for p values <0.05, <0.01, < 0.001 and <0.0001, 
respectively.
Additional methods are described in the online supplementary 
materials.
RESULTS
TREM-2 is upregulated in human HCC, is prominently 
expressed in tumour infiltrating macrophages, correlating 
with markers of inflammation and fibrosis
To explore a potential role for TREM-2 in HCC, we first anal-
ysed TREM-2 expression in human HCC tumours and control 
liver tissue (ie, non- tumour surrounding and healthy liver tissues) 
using two different approaches (ie, RNA- seq and qPCR) and two 
different patient cohorts (ie, TCGA and San Sebastian, respec-
tively). Consistent with observations in other cancers including 
gastric, renal and brain cancers, where elevated TREM-2 
was observed in tumour versus control tissues,13–15TREM-2 
expression was upregulated in HCC samples compared with 
non- tumour surrounding liver tissues of the ‘TCGA cohort’ 
(figure 1A). Similarly, opposed to normal liver tissues, TREM-2 
levels were increased in HCC tumour tissues of the ‘San Sebas-
tian cohort’ (figure 1A). Tumour stage stratification of the 
TCGA cohort revealed that TREM-2 expression was increased 
in advanced (T4 stage) versus early (T1 stage) HCC tumours 
(online supplementary figure 1). Evaluating TREM-2 expres-
sion using immunohistochemistry in human healthy liver and 
HCC tumours of variable aetiology and surrounding cirrhotic 
liver tissue (online supplementary table 2) verified that TREM-2 
expression was more extensive in diseased compared with control 
liver (figure 1B). Importantly, while TREM-2 was not expressed 
in transformed hepatocytes, TREM-2 immunostaining was 
observed in inflammatory periportal areas in the surrounding 
cirrhotic tissue and adjacent tissue to the fibrotic septa of patients 
with HCC. Expression was also prominent within infiltrating or 
resident cells within HCC tumours of various aetiologies and 
these cells morphologically resembled macrophages (figure 1B 
and online supplementary figure 2A). We noted that although 
compared with control liver, TREM-2 immunostaining was 
extensive in both the surrounding cirrhotic and tumour tissue of 
HCC patients in the ‘San Sebastian cohort’, there was no striking 
differences in immunostaining intensity between the tumour and 
its surroundings (figure 1B and online supplementary figure 2A). 
TREM-2 mRNA levels (qPCR) of patient matched surrounding 
versus tumour tissue in the ‘San Sebastian cohort’ demonstrated 
patient- specific variability with some patients exhibiting down-
regulation of TREM-2 in tumour versus surrounding cirrhotic 
tissue and others upregulation (online supplementary figure 
2B). As liver inflammation and fibrosis are important for HCC 
progression,1 we next correlated TREM-2 expression with several 
pro- fibrotic (COL1A1 and ACTA2) and pro- inflammatory (IL1B, 
IL6, IL8 and TNF) genes in the HCC tumour samples from the 
‘San Sebastian cohort’. While no correlation was observed for 
ACTA2, TREM-2 expression positively correlated with COL1A1, 
IL1B, IL6, IL8 and TNF levels (online supplementary figure 3). 
Similar results were observed in HCC samples from the TCGA 
cohort, although TREM-2 expression here also significantly 
correlated with ACTA2 (online supplementary table 3). Thus, 
compared with control human liver, TREM-2 expression is 
increased in HCC tumours and correlates with inflammatory 
and fibrotic genes.
We next examined which cell types express TREM-2 in HCC 
human liver tumours. We utilised publicly available single- cell 
RNA sequencing data from nine HCC livers, encompassing 
both malignant and non- malignant cell types18 and post- data 
processing, visualised the clustered data using t- distributed 
Stochastic Neighbour Embedding (t- SNE) through the Seurat R 
package. In line with previously published observations encom-
passing this data set,18 we identified six clusters annotated to 
T cells, B cells, cancer- associated fibroblasts, tumour- associated 
macrophages, tumour- associated endothelial cells and hepatic 
progenitor like (HPC- like) cells using known cell lineage- 
specific marker genes (figure 1C, online supplementary figure 
4). HCC malignant cells were cell annotated based on RNA- 
seq derived large- scale chromosomal copy- number variations 
prediction from the previously published work encompassing 
this data set.18 These cell types clustered together with HPC- 
like cells (figure 1C). Notably, this cluster was rich in expres-
sion of markers typical of transformed hepatocytes possessing 
stem/progenitor properties including alpha- fetoprotein (AFP), 
albumin (ALB), keratin 19 (KRT19), CD24 and SOX9 (online 
supplementary figure 5).21–24 Importantly, and in accordance 
with our immunohistochemistry data (figure 1B), TREM-2 
expression was most prominent in macrophages and markedly 
increased compared with malignant cells/transformed hepato-
cytes (figure 1D,E). Refined- clustering of the macrophage cluster 
in human HCC, demonstrated distinct clusters with prominent 
TREM-2 expression in clusters 1 and 2 that were characterised by 
expression of the resident KC marker CD68 and the monocyte 
marker CD14 (figure 1F).25–27 Furthermore, in line with recent 
work demonstrating the presence of monocyte derived TREM-
2+CD9+ scar- associated macrophages (SAMacs) in human liver 
cirrhosis,28 the macrophage cluster was characterised by CD9 
presence (figure 1G). In silico- based cellular deconvolution of 
the RNA- seq TCGA data subsequently correlating TREM-2 
expression with innate and adaptive immune cell gene signa-
tures present in HCC further suggested that in human HCC, 
TREM-2 was mainly expressed by macrophages/monocytes as 
out of the deconvoluted cell types, TREM-2 positively correlated 
with macrophages and monocytes but not with CD4+ or CD8+ 
T cells nor with neutrophils or endothelial cells (online supple-
mentary table 4). We identified 42 differentially expressed genes 
between TREM-2 expressing (clusters 1 and 2; figure 1F), and 
non- expressing (clusters 0, 3, 4 and 5, figure 1F) tumour infil-
trating macrophages (online supplementary figure 6). Gene set 
enrichment analysis demonstrated enrichment in TLR signalling 
and lysosome- associated pathways (figure 1H), implying overlap-
ping functions between TREM-2 expressing tumour infiltrating 
macrophages and resident TREM-2 expressing KCs, in the nega-
tive regulation of TLR- induced inflammation.16 Enrichments 
of lysosome- associated pathways are consistent with recent 
published observations examining TREM-2 function in KCs,29 
further suggesting functional similarities between TREM-2 
expressing resident KCs and tumour infiltrating macrophages.
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Together, these observations indicated a particular importance 
for TREM-2 expression in tumour infiltrating monocyte- derived 
macrophages in HCC, suggesting their associated effects with 
inflammation and fibrosis might be involved in HCC develop-
ment and/or progression.
TREM-2 attenuates oxidative stress, inflammation and 
hepatocyte damage during the early phases of liver 
tumourigenesis
To determine the role of TREM-2 in the early phases of HCC, 
we performed the well- established model of acute DEN adminis-
tration, which provides significant insight into the inflammatory 
mechanisms at play during HCC.30 31 We thus acutely injected 
8 week- old Trem-2-/- or WT control mice with 100 mg/kg DEN 
and humanely sacrificed both genotypes at different time points 
(figure 2A). H&E staining revealed more extensive liver damage 
in Trem-2-/- versus WT animals, associated with augmented hepatic 
phospho- histone H2AX (γH2AX) levels, a surrogate marker 
for DNA damage (figure 2B, C). Consistently, while there were 
no baseline differences in circulating alanine aminotransferase 
(ALT) levels between genotypes, significantly elevated ALT was 
found in Trem-2-/- mice post- DEN versus controls (figure 2D). 
Notably, increased levels of hepatic ROS were observed in Trem-2-
/- compared with WT mice post- DEN (figure 2E). This was asso-
ciated with increased inflammatory (C–X–C motif chemokine 
ligand 1 (Cxcl1), chemokine (C–C motif) ligand two or monocyte 
chemoattractant protein 1 (Mcp1), tumour necrosis factor (Tnf)), 
mitogenic (hepatocyte growth factort (Hgf)) and oxidative stress- 
related gene expression ((Hmox1) heme oxygenase 1) in Trem-2-
/- compared with WT animals (figure 2F). However, we did not 
Figure 1 TREM-2 expression is elevated in human HCC and is prominently expressed in tumour infiltrating macrophages. (A) qPCR analysis of 
TREM-2 expression in surrounding normal tissue and in HCC tissue (n=49 and 366, respectively) in the cohort from TCGA and in normal human 
liver (controls) and HCC samples (n=21 and 35, respectively) of the San Sebastian cohort. (B) Representative images of TREM-2 expression by 
immunohistochemistry in human healthy liver and diseased liver from a patient with an HCC tumour and its surrounding cirrhotic liver of HBV 
aetiology. Scale bars represent 100 µm. (C) t- SNE projection depicting cellular composition of human HCC tumours. Cells that share similar 
transcriptome profiles are grouped by colours and were annotated using lineage specific markers. (D and E) t- SNE plot depicting TREM-2 expression in 
TAMs (D) and corresponding Log2 normalised counts (Log2NC) TREM-2 expression values for all tumour infiltrating cells types (E). Shown in brackets 
are the number of cells analysed for each cell type post- data processing. (F and G) t- SNE projection post- reclustering of TAMs and TREM-2, CD14, 
CD68 (F) and CD9 (G) expression therein. (H) GSEA plots depicting enrichments in TLR signalling and lysosome pathways within TREM-2 expressing 
TAMs. The y- axis represents the enrichment score (ES) and vertical black lines on the x- axis shows where genes annotated to the respective pathways 
appear in the ranked list of genes. The coloured band represents the ES values (red for positive and blue for negative). (A) Non- parametric Mann- 
Whitney test was used. (E) One- way analysis of variance followed by Tukey’s post- test was used. ****Denotes a p value of <0.0001. AU, arbitrary 
units, CD, cluster of differentiation, GSEA, gene set enrichment analysis; HCC, hepatocellular carcinoma; qPCR, quantitative PCR; TAMs, tumour- 
associated macrophages; TCGA, the cancer genome atlas; TLR, Toll- like receptor; TREM-2, triggering receptor expressed on myeloid cells 2; tSNE, t- 
distributed Stochastic Neighbour Embedding.
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observe differences in hepatic immune cell recruitment between 
genotypes (online supplementary figure 7). These data suggested 
an importance for TREM-2 in suppressing inflammation, ROS 
production and consequent liver damage during the initiation of 
DEN- induced carcinogenesis. To corroborate these findings, we 
next performed gain- of- function experiments. We intravenously 
injected WT C57BL/6 animals with either a control adenovirus 
or an adenovirus encoding TREM-2 under the transcriptional 
control of the cytomegalovirus promoter. Seventy- two hours post- 
virus infection, we acutely injected mice with DEN and evaluated 
both groups of animals 72 hours post- DEN (figure 3A). Rati-
fying transduction efficiency, TREM-2 was robustly expressed 
Figure 2 Trem-2-/- mice exhibit increased hepatocyte damage, inflammation and oxidative stress in an acute DEN model. (A) Scheme depicting 
experimental outline of acute DEN in both genotypes of mice following injection with 100 mg/kg DEN (saline; n=6–7, DEN 6 hour; n=7, DEN 24 hours; 
n=10, DEN 72 hours; n=6–7). (B) Quantification of damaged livers of both genotypes at the indicated time points and representative H&E images. 
(C) Quantification of damaged hepatocytes at the indicated time points measured by manually counting γH2AX positive nuclei and representative 
IHC images. (D) ALT levels were determined in the serum post- DEN. (E) ROS was determined in liver tissue of WT and Trem-2-/- mice after 24 hours of 
DEN administration with the H2DCFDA dye. (F) mRNA levels of the chemokines Cxcl1 and Mcp1, the cytokine Tnf and the oxidative stress enzyme 
Hmox1 and the growth factor Hgf were determined. Parametric Student’s t- test and non- parametric Mann- Whitney test were used. Data represent 
mean±SEM and *, ** and **** denote a p value of <0.05,<0.01 and <0.0001, respectively. ALT, alanine aminotransferase; AU, arbitrary units; Cxcl1, 
C–X–C motif chemokine ligand 1; DEN, diethylnitrosamine; Hgf, hepatocyte growth factor; Hmox1, heme oxigenase 1; IHC, immunohistochemistry; 
Mcp1, monocyte chemoattractant protein 1; ROS, reactive oxygen species; Tnf, tumour necrosis factor; TREM-2, triggering receptor expressed on 
myeloid cells-2.
 on A






















1350 Esparza- Baquer A, et al. Gut 2021;70:1345–1361. doi:10.1136/gutjnl-2019-319227
Hepatology
in animals injected with TREM-2 overexpressing versus control 
virus (figure 3B). While there was a slight tendency for ALT levels 
to be decreased in TREM-2 overexpressing animals opposed to 
controls, significantly attenuated serum aspartate aminotrans-
ferase and alkaline phosphatase levels verified TREM-2 attenuated 
DEN- mediated liver damage (figure 3C). Importantly, the hepato-
protective effects of TREM-2 overexpression were linked to less 
ROS and MCP-1 production (figure 3D,E). Thus, complimentary 
approaches, encompassing animals both genetically lacking and 
overexpressing TREM-2, demonstrate that it attenuates hepatic 
damage, inflammation and oxidative stress in the early phases of 
HCC.
Trem-2 plays a protective role in HCC
To formally investigate the role of TREM-2 in hepatocarcino-
genesis, we next performed a chronic DEN model, where we 
injected the hepatocarcinogen DEN or saline control to both 
genotypes and sacrificed them 30 and 40 weeks post- DEN 
administration (figure 4A). In parallel, as ROS are important for 
HCC development32 and we had observed elevated hepatic ROS 
in Trem-2 deficient animals (figure 2E), and decreased ROS in 
those experimentally overexpressing TREM-2 (figure 3D), we 
chronically fed both mouse genotypes a diet supplemented with 
the antioxidant BHA (figure 4B). Opposed to saline controls, 
hepatic Trem-2 levels were increased in the non- tumour tissue of 
DEN- administered mice (figure 4C). Regarding Trem-2 expres-
sion in tumour tissue versus matched non- tumour tissue, Trem-2 
was markedly increased in tumour samples, particularly 40 weeks 
post- DEN (figure 4D). Remarkably, macroscopic liver analysis 
demonstrated that DEN- administered Trem-2-/- mice developed 
more tumours than controls at both time points (figure 4E). 
Analysis of tumour size revealed that Trem-2 deficient animals 
exhibited increased numbers of small (≤2 mm) and big (≥6 mm) 
tumours, and more small and medium size (2–6 mm) tumours 
30 and 40 weeks post- DEN, respectively (online supplementary 
figure 8). Notably, BHA administration reversed the elevated 
tumourigenesis of Trem-2-/- mice, supporting an involvement of 
ROS in the protective effects mediated by TREM-2 (figure 4F). 
Of note, the antioxidant regimen also extensively lowered 
tumour burden of WT mice, which is consistent with DEN- 
mediated tumourigenesis being blocked by antioxidants.30 33
We next set out to confirm these macroscopic observa-
tions and elaborate on the potential mechanisms behind 
them. H&E staining confirmed increased hepatic tumours in 
Figure 3 TREM-2 overexpression lowers liver injury, inflammation and oxidative stress in acute DEN. (A) Scheme depicting experimental outline 
for TREM-2 overexpression. C57BL/6 mice were intravenously injected with control or TREM-2 expressing adenoassociated viruses (1×1011 pfu) and 
after 72 hours mice were intraperitoneally injected with 100 mg/kg DEN. Animals were sacrificed 72 hours post- DEN (n=10). (B) mRNA levels of 
Trem-2. (C) ALT, AST and AP levels were determined in the serum post- DEN. (D) ROS was determined in liver tissue of C57BL/6 mice 72 hours post- DEN 
administration with the H2DCFDA dye. (E) mRNA levels of the chemokine Mcp1 were determined. Parametric Student’s t- test and non- parametric 
Mann- Whitney test were used. Data represent mean±SEM and *, **, *** and **** denote a p value of <0.05,<0.01,<0.001 and <0.0001, 
respectively. AAV, adeno- associated viruses; ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; AU, arbitrary 
units; DEN, diethylnitrosamine; i.p., intraperitoneal; i.v., intravenous; Mcp1, monocyte chemoattractant protein 1; ROS, reactive oxygen species; TREM-
2, triggering receptor expressed on myeloid cells 2.
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Trem-2-/- animals (figure 5A). To evaluate hepatocyte prolifera-
tion in pre- neoplastic surrounding liver tissue, we next measured 
proliferating cell nuclear antigen (PCNA) expression using IHC. 
Post- DEN, Trem-2-/- mice exhibited increased numbers of PCNA- 
positive hepatocytes in the surrounding tissue versus controls, 
irrespective of time point (figure 5B). Similarly, IHC analysis 
of γH2AX revealed an increased number of γH2AX- positive 
hepatocytes in Trem-2-/- livers compared with WT at both time 
points (figure 5C). Consistent with findings during acute DEN, 
evaluating hepatic immune cell recruitment revealed minor 
differences between genotypes post- DEN (online supplemen-
tary figure 9). Furthermore, caspase-3/7 activation and protein 
levels of the kinase receptor- interacting protein kinase 3 as well 
as phosphorylation of its downstream substrate mixed lineage 
kinase domain- like34 were similar between genotypes 30 and 40 
weeks post- DEN (online supplementary figure 10).
In line with ROS playing critical roles in DNA damage and 
cellular proliferation during HCC,35 the BHA regimen (figure 4B) 
Figure 4 Trem-2 null mice exhibit elevated tumourigenesis post- DEN. (A) Scheme depicting experimental outline of chronic DEN in both genotypes 
of mice following injection with 30 mg/kg DEN (n=14–17). (B) Diagram depicting antioxidant intervention with BHA during chronic DEN (n=7–12). (C) 
qPCR analysis of hepatic Trem-2 expression of 30 and 40 weeks DEN- injured mice and (D) qPCR analysis of Trem-2 expression in non- tumour versus 
tumour tissue in the liver of 30 and 40 weeks DEN- injured mice. (E) Representative pictures of the livers (arrows depict tumours) and total tumour 
number per mice are shown. (F) Representative liver pictures of DEN injured mice after 15 weeks of BHA diet (n=7–12) and tumour numbers herein. 
(C- E) Parametric Student’s t- test and non- parametric Mann- Whitney test were used. Data represent mean±SEM and *,**, *** and **** denote a p 
value of <0.05, <0.01, <0.001 and <0.0001. AU, arbitrary units; BHA, butylated hydroxyanisole; DEN, diethylnitrosamine; i.p., intraperitoneal; qPCR, 
quantitative PCR; TREM-2, triggering receptor expressed on myeloid cells 2; WT, wild type.
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attenuated PCNA and γH2AX levels in both mouse genotypes 
and reversed the effects of Trem-2 abrogation (figure 5B and C). 
Likely reflective of better HCC outcome in general in the context 
of antioxidants, levels of certain pro- inflammatory cytokines 
including Tnf and Rantes were attenuated in both genotypes of 
BHA- treated animals (online supplementary figure 11A). Further-
more, we did not detect any differences in pro- inflammatory 
cytokines 30 or 40 weeks post- DEN between genotypes (online 
Figure 5 Trem-2 null mice exhibit increased numbers of proliferative and damaged hepatocytes post- DEN- induced carcinogenesis. (A) Total HCC 
tumour counting in DEN- injected WT and Trem-2-/- livers sacrificed after 30 weeks (n=16). (B and C) Microscopic analysis of WT and Trem-2-/- mice 
injected with 30 mg/kg DEN and sacrificed after 30 and 40 weeks fed with a normal or a BHA diet for 15 weeks (n=7–17). (B) Representative PCNA 
IHC images and quantification of proliferative hepatocytes measured by manually counting PCNA positive nuclei (20×) (C). Representative γH2AX IHC 
images and quantification of damaged hepatocytes measured by manually counting γH2AX positive nuclei (20×). Scale bars represent (A) 1000 µm 
and (B and C) 100 µm. (D) Correlation between the mRNA expression levels of Trem-2 and markers of fibrosis Col1a1 and Acta2 in the non- tumour 
liver tissue of DEN- administered WT mice sacrificed after 30 and 40 weeks (n=29). (A–C) Parametric Student’s t- test and non- parametric Mann- 
Whitney test were used. (D) Spearman’s correlation test was used. Data represent mean±SEM and *, ** and *** denote a p value of <0.05, <0.01 
and <0.001, respectively. AU, arbitrary units; Acta2, actin alpha 2, smooth muscle; BHA, butylated hydroxyanisole; Col1a1, collagen type I alpha 1 
chain; DEN, diethylnitrosamine; γH2AX, phospho- histone H2A.X; HCC, hepatocellular carcinoma; IHC, immuonohistochemistry; n.s, non- significant; 
PCNA, proliferating cell nuclear antigen; TREM-2, triggering receptor expressed on myeloid cells 2; WT, wild type.
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supplementary figure 11A). In line with this, no differences in 
c- jun n- terminal kinase activation were observed between geno-
types (online supplementary figure 11B). These data suggested a 
particular importance for TREM-2 in restraining inflammation 
during the priming phase of DEN- induced HCC (figure 2F). 
Consistent with the importance of ROS in TREM-2’s protec-
tive effects in HCC, 40 weeks post- DEN, we observed a strong 
tendency (p=0.0582) towards higher hepatic inducible nitric 
oxide synthase (Inos) levels in Trem-2-/- animals (online supple-
mentary figure 12A). As Inos is a marker for classically activated 
M1 macrophages,36 we next examined whether in chronic DEN, 
there were any differences in genes associated with alternatively 
activated M2 macrophages, cells that play a modulatory role in 
hepatic fibrosis.36 37 Among the tested markers (Arg1, FIZZ-1 
and CD206), we could not observe any changes nor were there 
differences in the pro- fibrogenic mediator Tgf-β (online supple-
mentary figure 12B). Despite no influences of TREM-2 on Tgf-β 
in DEN- instigated HCC, based on our published observations 
demonstrating that TREM-2 is markedly upregulated in acti-
vated HSCs16 and that TREM-2 correlates with collagen levels in 
human HCC (online supplementary figure 3), we next correlated 
hepatic Trem-2 levels with pro- fibrotic markers that are promi-
nent during HSC activation in non- tumour liver tissue of WT 
mice after DEN administration (30 and 40 weeks). By doing 
so, we could observe that Trem-2 levels correlated with Col1a1 
and Acta2 levels (figure 5D), suggesting TREM-2 expression 
within activated HSCs might regulate HCC development and/
or progression.
Together, these data indicate that alterations in M1/M2 macro-
phage polarisation, necroptosis or apoptosis between genotypes 
do not account for the worsened outcome of TREM-2 deficient 
mice in HCC. Notably, they further suggest that elevated DNA 
damage and proliferation mediated through oxidative stress is 
key to the worsened outcome of Trem-2- deficient animals. This 
hypothesis is supported by proteomic analysis of liver tumour 
tissue post- DEN. Herein, several proteins were significantly and 
differentially expressed between genotypes (online supplemen-
tary figure 13), and gene ontology analysis revealed enrichment 
of biological processes including oxidoreductase activity and 
lipid metabolism (online supplementary table 5).
TREM-2 exerts tumourigenic protective effects in fibrosis-
associated HCC
To strengthen the protective effects of TREM-2 in HCC and 
to examine its potential impact on fibrosis- associated hepato-
carcinogenesis, we next performed two different HCC models. 
CCl4 induces hepatic fibrosis and is frequently combined with 
DEN administration to study fibrosis- associated HCC.38 We thus 
combined chronic DEN with 10 weekly CCl4 injections starting 
at week 4 and harvested both genotypes at week 30 (figure 6A). 
DEN/CCl4 administration led to increased numbers of small (≤2 
mm) tumours in Trem-2-/- animals versus controls at 30 weeks 
(figure 6B), consistent with the effects of DEN alone at this 
time point (online supplementary figure 8). Evaluating fibrosis 
using Sirius red staining, surprisingly demonstrated that despite 
the enhanced tumourigenesis of Trem-2-/- mice versus controls, 
these animals displayed less fibrosis (figure 6C). Furthermore, 
increased PCNA transcription in DEN/CCl4- treated Trem-2
-/- 
animals suggested increased hepatocyte proliferation (figure 6D). 
As a second model of fibrosis- associated HCC, TAA was admin-
istered to both genotypes in drinking water,38 starting at week 8 
of age, and animals harvested 40 weeks post- TAA administration 
(figure 6E). Trem-2- deficient animals exhibited larger tumours 
post- TAA versus controls (figure 6F) and akin to the DEN/CCl4 
model, this was associated with attenuated fibrosis and increased 
PCNA levels (figure 6G,H). Together, these data encompassing 
diverse murine models unequivocally demonstrate that TREM-2 
restrains tumour development and proliferation in HCC. They 
further suggest that although TREM-2 promotes fibrosis in 
HCC, these effects are disassociated from HCC development, 
supporting recent work indicating that the molecular players in 
fibrosis and HCC can be uncoupled.39 40
Increased hepatocyte proliferation in Trem-2-/- mice following 
PHx
Given the importance of liver regenerative mechanisms in 
HCC,41 and the elevated hepatocyte proliferation of Trem-2- 
deficient animals versus controls post- DEN as well as in the 
fibrosis- associated HCC models (figures 5 and 6), we next 
investigated how TREM-2 impacts hepatocyte proliferation 
using PHx. We thus subjected both genotypes to ~70% PHx, 
subsequently sacrificing them at different time points. Trem-2 
levels increased robustly post- PHx, with a peak of expression 
48 hours post- surgery relative to sham- operated mice, suggestive 
of a potential role in liver regeneration (figure 7A). Strikingly, 
two independent methods of evaluating hepatocyte prolifer-
ation (ie, PCNA immunostaining and BRDU incorporation) 
revealed increased hepatocyte proliferation in Trem-2-/- versus 
WT control animals after PHx (figure 7B,C). PCNA immu-
noblotting confirmed this result (figure 7D). As the priming 
phase of liver regeneration preceding hepatocyte proliferation 
is associated with inflammatory cytokine upregulation,42 we 
next hypothesised that perhaps during PHx TREM-2’s suppres-
sive effects on hepatocyte proliferation was linked to effects of 
this receptor on early inflammatory events after PHx. Indeed, 
elevated hepatocyte proliferation of Trem-2- deficient animals 
was associated with an early augmentation of inflammation as 
revealed by increased levels of pro- inflammatory genes (ie, Tnf, 
Il6). Notably, hepatic levels of Hgf were also increased early 
in Trem-2-/- opposed to WT animals after PHx (figure 7E). As 
IL-6 activates STAT3 in PHx,43 levels of phosphorylated STAT3 
were analysed by immunoblotting in both genotypes 6 hours 
post- PHx. Increased Il6 levels 6 hours post- PHx in Trem-2 defi-
cient animals did not result in more hepatic STAT3 activation 
(online supplementary figure 14A). Lipid accumulation during 
liver regeneration induces transient steatosis and lipids might be 
used as a source of energy to ensure proper hepatic regenera-
tion and proliferation.44 45 Considering an enrichment in lipid 
metabolism- related processes was observed post- DEN in Trem-
2-/- compared with WT animals (online supplementary table 
5), we next evaluated hepatic triglyceride content. Compared 
with control animals, hepatic triglycerides accumulated 6 hours 
post- PHx, but there were no genotype specific differences 
(online supplementary figure 14B). Similarly, there were no 
differences in serum triglycerides post- DEN (online supplemen-
tary figure 14C). Thus, TREM-2 restrains hepatocyte prolifera-
tion, an effect likely independent of triglyceride production but 
linked to hepatic inflammation and growth factor production.
Overexpression of TREM-2 in HSC modulates Wnt ligand 
secretion and reduces HCC tumourigenicity
Although our single- cell RNA sequencing analysis of human 
HCC tumour samples demonstrated that TREM-2 is primarily 
expressed in tumour infiltrated macrophages (figure 1), we previ-
ously demonstrated that TREM-2 is robustly expressed in acti-
vated human and murine HSCs during liver injury where it serves 
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to modulate TLR- mediated inflammation.16 It is well established 
that activated HSCs infiltrate the tumour stroma, secrete extra-
cellular matrix (ECM) proteins and favour HCC tumourige-
nicity through changes in their secretory phenotype.46–48 Given 
this, together with our aforementioned published work and that 
Trem-2 levels in non- tumour liver tissue of WT mice post- DEN 
correlated with Col1a1 and Acta2 levels (figure 5D), we next 
explored whether HSC expressed TREM-2 might impact HCC 
Figure 6 Trem-2 null mice exhibit elevated carcinogenesis in fibrosis- associated HCC models. (A–D) WT and Trem-2-/- mice were injected with 
30 mg/kg DEN followed by 10 weekly injections of CCl4 and sacrificed at 30 weeks post- DEN injection. (A) Scheme depicting experimental outline 
of DEN/CCl4 in both genotypes of mice (n=13–14). (B) Representative pictures of the livers (arrows depict tumours) and tumour number classified 
by size and per mouse are shown. (C) Liver fibrosis was analysed by Sirius red staining. Representative images (4×) and quantification by Image J 
software (10×) are shown. (D) Hepatic Pcna expression by qPCR of DEN/CCl4 treated WT and Trem-2
-/- mice. (E–H) TAA (0.03% w/v) was administered 
to WT and Trem-2-/- mice for 40 weeks. (E) Scheme depicting experimental outline of TAA administration (n=9). (F) Representative pictures of the 
livers (arrows depict tumours) and total tumour volume (calculated with the formula Tv= (W2 x L)/2) per mouse are shown. (G) Liver fibrosis was 
analysed by Sirius red staining; representative images (4×) and quantification by Image J image analysis software (10×) are shown. (H) Hepatic Pcna 
expression by qPCR of WT and Trem-2-/- mice after TAA administration. Scale bars (C and G) represent 100 µm. Parametric Student’s t test and non- 
parametric Mann- Whitney test were used. Data represent mean±SEM and * denotes a p value of <0.05. AU, arbitrary units; CCl4, carbon tetrachloride; 
DEN, diethylnitrosamine; HCC, hepatocellular carcinoma; i.p., intraperitoneal; PCNA, proliferating cell nuclear antigen; qPCR, quantitative PCR; TAA, 
thioacetamide; TREM-2, triggering receptor expressed on myeloid cells 2; WT, wild type.
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growth. To evaluate this and translate these findings to the 
human situation, we next developed a 3D spheroid model. Such 
models have proved to be invaluable for studying the interactions 
between cancer cells and their surrounding environment.49 50 We 
thus overexpressed TREM-2 in human HSCs (ie, LX-2 cells) in 
vitro and after confirming successful overexpression (figure 8A), 
carried out culture hanging droplet liver cancer spheroid growth 
assays with two different HCC cancer cell lines (Hep3B and PLC/
PRF5) with the supernatant of these cells versus HSCs that had 
received a control plasmid. Strikingly, supernatant of TREM-2 
Figure 7 Role of TREM-2 in liver regeneration and hepatocyte proliferation after PHx. (A) Expression of hepatic Trem-2 in WT animals at the 
indicated time points post- PHx (n=3–4). (B–E) WT and Trem-2-/- mice were sham- operated or subjected to PHx and sacrificed at the indicated 
time points (n=3–6). (B) Representative IHC images of the PCNA proliferative marker 36 hours post- PHx (20×) and quantification of proliferating 
hepatocytes measured by counting PCNA positive nuclei. Scale bars represent 100 µm. (C) Representative images of the BRDU staining 36 hours post 
(20×) and quantification of proliferating hepatocytes measured by manually counting BRDU incorporation in nuclei. Scale bars represent 100 µm. 
(D) PCNA was determined by immunoblotting 72 hours post- PHx, and β- actin was used as house- keeping control (n=5). Representative images and 
quantification of the relative PCNA/β- actin levels are shown. (E) mRNA expression of the proinflammatory cytokine Tnf 1 hour after PHx (n=5–6), and 
cytokine Il6 and Hgf 6 hours following PHx (n=6–11). Parametric Student’s t test and non- parametric Mann- Whitney test were used. Data represent 
mean±SEM and *, **, *** denote a p value of <0.05,<0.01 and <0.001, respectively. AU, arbitrary units; BRDU, 5′- bromo-2′- deoxyuridine; Hgf, 
hepatocyte growth factor; IHC, immuonohistochemistry; Il6, interleukin 6, PCNA, proliferating cell nuclear antigen; PHx, partial hepatectomy; Tnf, 
tumour necrosis factor; TREM-2, triggering receptor expressed on myeloid cells 2; WT, wild type.
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overexpressing LX-2 cells markedly reduced 3D Hep3B HCC 
spheroid growth compared with control conditions, suggesting 
TREM-2 modulated the HSC secretome in a manner that nega-
tively influences HCC proliferation (figure 8B). Similar effects 
were observed with PLC/PRF5 HCC cells, demonstrating they 
are not cell- type specific (online supplementary figure 15). 
Considering the anti- inflammatory effects of Trem-2 during 
both PHx (figure 7E) and acute DEN (figure 2F), we next exam-
ined whether the aforementioned decreases in HCC spheroid 
growth instigated by TREM-2 overexpressing HSC supernatant 
were associated with attenuated basal HSC cytokine expression 
and secretion. Indeed, both TNF and MCP-1 mRNA and protein 
Figure 8 HCC spheroid culture in LX-2 conditioned media. (A) TREM-2 was overexpressed in LX-2 cells and expression efficiency determined 
by qPCR and immunoblotting (n=4). (B) Hep3B cells were seeded in hanging droplets for 7 days and forming spheroids were transferred to LX-2 
conditioned media from either cells that were overexpressing TREM-2 or a control plasmid. Spheroid size was recorded (20×) using a Nikon 
eclipse TS100 microscope. (C) TNF and MCP1 and the mRNA levels of canonical Wnt ligands WNT3, WNT7A and WNT8A 24 hours post- TREM-2 
overexpression. (D) Hep3B spheroids were incubated with the Wnt/β- catenin inhibitor IWR-1 in LX-2 conditioned media for 72 hours and spheroid 
growth was recorded as indicated. (E) LX-2 cells or Hep3B spheroids were incubated with the inhibitor of Wnt ligand secretion IWP-2, Hep3B 
spheroids were incubated in LX-2 conditioned media for 72 hours and spheroid growth was monitored as indicated. (A–C) Parametric Student’s t test 
and non- parametric Mann- Whitney test were used. (D and E) Kruskal- Wallis test followed by Dunn’s multiple comparison test for individual subgroup 
comparison was used. Data represent mean±SEM and *, ** and **** denote a p value of<0.05, 0.01 and <0.0001, respectively. Data in (A–E) are 
representative of at least two independent experiments. AU, arbitrary units; GAPDH, glyceraldehyde-3- phosphate dehydrogenase; HCC, hepatocellular 
carcinoma; HSC, hepatic stellate cells; MCP1, monocyte chemoattractant protein 1; n.s, non- significant; OE, overexpression; qPCR, quantitative PCR; 
SN, supernatant; TNF, tumour necrosis factor; TREM-2, triggering receptor expressed on myeloid cells 2.
 on A






















1357Esparza- Baquer A, et al. Gut 2021;70:1345–1361. doi:10.1136/gutjnl-2019-319227
Hepatology
levels in HSCs were attenuated on experimental TREM-2 over-
expression (figure 8C, online supplementary figure 16).
Given the major role of the Wnt/β- catenin pathway in 
HCC51 52 and that TREM-2 is described to modulate this 
pathway in other cellular systems including the bone and 
brain,53 54 we next evaluated potential effects of TREM-2 on 
Wnt signalling and HCC growth. TREM-2 overexpression in 
HSCs attenuated the expression of the canonical Wnt ligands, 
WNT3, WNT7A and WNT8A suggesting TREM-2 in HSCs 
might attenuate HCC growth through paracrine Wnt- dependent 
signalling (figure 8C). To expand on this idea, we next incubated 
HCC spheroids with TREM-2 overexpressing or control HSC 
(LX-2) supernatant in the presence or absence of the β- catenin 
inhibitor IWR-1. Concordant with expression of Wnt ligands 
in HSCs (figure 8C, white bars), HCC spheroid growth was 
dependent on Wnt signalling as it was substantially reduced by 
IWR-1 under control conditions (figure 8D, red bars). Further-
more, the HCC growth- attenuating effect of supernatant 
from TREM-2 overexpressing HSCs was abolished in IWR-1- 
treated cells (figure 8D), implicating the effects of TREM-2 
on Wnt/β- catenin signalling in HCC growth. Further evidence 
was obtained from experiments where we blocked Wnt ligand 
secretion (with the IWP-2 inhibitor) in both sets of HSCs and 
observed that blocking Wnt ligand secretion abolished the differ-
ences associated with TREM-2 overexpression (figure 8E). To 
rule out potential autocrine effects of IWP-2 treatment on the 
HCC spheroid (ie, effects of Wnt ligand secretion within the 
HCC cells), we performed control conditions where in parallel 
we directly added IWP-2 to HCC spheroids in the presence of 
supernatant from both sets of HSCs. Strikingly, TREM-2 overex-
pressing LX-2 supernatant still attenuated HCC growth in these 
conditions (figure 8E). Together, these data assign a potential 
function for TREM-2 in influencing the HSC secretome and 
reducing HCC tumourigenicity via paracrine mechanisms that 
rely on Wnt signalling.
DISCUSSION
The role of the immune receptor TREM-2 in human neurode-
generative disorders is currently under intense investigation.10–12 
However, its impact on cancer,13–15 55 and particularly HCC, is 
almost unknown. HCC is a common deadly cancer, often arising 
during chronic liver injury. Therefore, there is an urgent need 
to identify hepatic anti- inflammatory players and mechanisms 
regulating hepatocarcinogenesis, as they might represent poten-
tial nodes for therapy. We recently reported that TREM-2 is 
preferentially expressed in non- parenchymal liver cells (ie, KCs 
and HSCs) acting as a natural inflammation brake during diverse 
hepatotoxic injuries.16 Based on these observations, we hypoth-
esised a protective role for TREM-2 in HCC. Here, we found 
upregulated TREM-2 expression in HCC tissues versus control 
liver tissues. Although high TREM-2 expression in surrounding 
cirrhotic and HCC tumour tissue versus control liver was 
evident, consistent with published observations indicating 
TREM-2 is downregulated in patient matched HCC tumour 
versus surrounding tissue,56 we observed patient- specific hetero-
geneity, with some patients exhibiting TREM-2 downregulation 
and others upregulation. Regardless of this heterogeneity, which 
might be explained by tumour cell biodiversity,18 here we find 
that TREM-2 expression in human HCC tumours correlated 
with markers of inflammation and fibrosis.
HCC usually originates in cirrhosis- associated hepatocellular 
nodules under regeneration. Here, environmental cues are key 
and if newly generated hepatocytes are exposed to abnormal 
chronic inflammation, normal liver regenerative responses shift 
towards malignancy linked to excessive hepatic proliferation, 
genomic instability and tumourigenesis.57 The early phase of 
liver regeneration post- PHx is characterised by elevated TNF 
and IL-6 expression, which are mainly produced by KCs and 
HSCs.58 Notably, the expression of these cytokines, as well as 
Hgf, are increased in Trem-2-/- animals versus WT controls after 
PHx and this is accompanied with increased hepatocyte prolif-
eration. Although TREM-2 negatively regulates TLR4- mediated 
inflammation in KCs and HSCs, our previous observations 
demonstrating equivalent inflammation in TNF or IL-1 chal-
lenged Trem-2-/- KCs and HSCs versus controls demonstrate that 
TREM-2 does not directly influence non- parenchymal hepatic 
cell cytokine signalling.16 Interestingly, Tlr4-/- mice display similar 
regenerative responses post- PHx to WT controls, suggesting 
lipopolysaccharide signalling is not required for hepatic regen-
erative responses.59 60 Similarly opposed to controls, identical 
hepatic regeneration reportedly occurs in TLR2- deficient and 
TLR9- deficient animals, indicating that responses to lipotechoic 
acid or bacterial DNA, ligands of the aforementioned TLRs 
whose signalling is modulated by TREM-2, is dispensable for 
liver regeneration.3 59–61 Thus TREM-2’s suppressive effects 
on hepatocyte proliferation might occur following engagement 
of multiple TLR ligands. Alternatively, TREM-2 could impact 
hepatic regenerative responses TLR independently, possibly 
through its postulated ligands that include phospholipids, 
proteoglycans, apolipoproteins and heat shock protein 60.6–9 
Interestingly, several of these are associated with regenerative 
responses either in the liver or in other systems and organ-
isms.45 62 63 Regardless of the exact upstream mechanism, our 
PHx data support the notion that TREM-2’s effects on inflam-
mation and growth factor production are intertwined with 
hepatic regenerative responses.
The tumour microenvironment plays a fundamental role in 
HCC development and progression, and comprises inflam-
matory cytokines, growth factors, proteolytic enzymes, non- 
parenchymal hepatic cells, immune cells and ECM proteins.48 
While during murine HCC we observed no impact of TREM-2 
on immune cell recruitment, hepatic Trem-2 levels correlated 
with HSC activation in surrounding non- tumour liver tissue, 
consistent with the idea that in mice TREM-2- expressing acti-
vated HSCs infiltrate the tumour microenvironment. However, 
in fibrosis- associated HCC models, opposed to controls, 
Trem-2-/- animals exhibited attenuated fibrosis associated with 
augmented tumourigenesis. Although this might seem coun-
terintuitive, as fibrosis is a strong risk factor for HCC, impor-
tantly these data are consistent with seminal recent single- cell 
RNA sequencing work demonstrating a pro- fibrogenic role for 
TREM-2+CD9+ expressing monocyte derived SAMacs in both 
human and murine CCl4- induced liver cirrhosis.
28 Conditioned 
media from primary human TREM-2 expressing SAMacs, which 
interestingly exhibits high baseline IL-1β and IL-8 produc-
tion, promotes collagen expression in primary human HSCs.28 
In agreement with this, we observed high TREM-2 expression 
in cells both infiltrating tumours and inflammatory periportal 
areas in the surrounding cirrhotic tissue. Furthermore, TREM-2 
expression positively correlated with COL1A1, IL1B and IL8 
levels. Importantly, our single- cell RNA sequencing analysis was 
able to expand on these recent findings by demonstrating the 
presence of infiltrated TREM-2 expressing monocyte- derived 
macrophages in human HCC tumours that were also CD9+ and 
CD68+, suggesting they resemble SAMacs. Although, we did 
not examine TREM-2+CD9+ monocyte- derived macrophage 
presence in murine HCC tumours, given their recently published 
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presence and profibrogenic role in murine CCl4 fibrosis,
28 the 
absence of fibrosis in Trem-2-/- versus control animals in the 
fibrosis- associated hepatocarcinogenesis models makes sense. 
These findings also support the concept of an uncoupling 
between the molecular players in fibrosis and HCC.39 40
While the ontogeny of human hepatic macrophages is 
unknown, in mice, embryonic self- renewing tissue- resident KCs 
predominate in homeostasis but post- injury, hepatic macro-
phages derived from circulating monocytes accumulate.64 65 
Interestingly, in the naïve state, two murine KC populations have 
recently been reported, Trem-2lo and Trem-2hi, with the Trem-
2hi population predominating in nonalcoholic steatohepa-
titis models where it is characterised by acquisition of CD9.29 
Furthermore, we previously demonstrated that TREM-2 damp-
ened murine CCl4- associated liver injury partly through ROS 
production within injury- associated inflammatory monocyte- 
derived macrophages, the recruitment of which depended on 
TLR4- driven inflammation within HSCs.16 Given that TREM-2 
attenuates hepatic damage, inflammation and oxidative stress in 
the early phases of HCC (figure 3), we hypothesise that HSC or 
KC expressed TREM-2 serves to dampen infiltration of TREM-
2+CD9+ monocyte- derived macrophages in HCC tumours. 
Although, the relative contribution of these cells to murine and 
human HCC remains to be determined, here we find that (1) 
human HCC tumours are rich in TREM-2 expressing monocyte- 
derived macrophages; (2) Akin to reported effects of TREM-2 
expression in KCs, TREM-2 expression in tumour- infiltrated 
macrophages is associated with TLR signalling and lysosomal 
pathways16 29; (3) TREM-2 expression in human HCC tumours 
correlates with inflammation; (4) overexpression of TREM-2 in 
human HSCs dampens MCP-1 levels and (5) TREM-2 unequiv-
ocally plays a protective role in hepatocarcinogenesis.
Interestingly, conditioned media of TREM-2 overexpressing 
HSCs but not control HSCs inhibited HCC spheroid growth and 
this was also associated with reduced expression of TNF, MCP1 
and canonical Wnt ligands. Blocking Wnt ligand secretion in 
HSCs abrogated the reduced HCC growth associated with HSC 
TREM-2 overexpression, adding influences of canonical Wnt 
Figure 9 TREM-2 modulates hepatocarcinogenesis in a multifactorial manner. Post- liver damage, Trem-2 absence leads to elevated DNA damage 
and hepatocyte death which provokes further DNA damage and augments inflammation and growth factor production. Conversely overexpression of 
TREM-2 dampens hepatic damage, inflammation and ROS, suggesting endogenous TREM-2 modulates hepatocellular injury in the initiation phase of 
HCC. TREM-2 expression in HSCs further impacts WNT ligand and cytokine expression/secretion, which impacts HCC growth. Recruitment of TREM-
2+CD9+ monocyte- derived macrophages into HCC tumours is also depicted. Although the exact function of these cells remains to be elucidated, 
they are likely functionally similar to TREM-2 expressing KCs. Together, TREM-2’s expression in non- parenchymal and infiltrating cells and its 
associated effects may impact the mutational rate of proliferating hepatocytes, altering hepatocyte regeneration, transformation and dampening HCC 
development. HCC, hepatocellular carcinoma; ROS, reactive oxygen species; TREM-2, triggering receptor expressed on myeloid cells 2 .
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signalling to part of TREM’s ‘protective network’ during HCC. 
These data are consistent with the critical role of β- catenin acti-
vation in liver tumourigenesis and its frequent reactivation in 
HCC51 52 They also underscore the importance of the microen-
vironment and the tumour promoting effects of HSCs. HSC acti-
vation is critical for hepatic tumourigenesis as cotransplantation 
of only activated HSCs with HCC cells into nude mice promotes 
tumour growth, an effect partly dependent on HGF.46 66 Here, 
we demonstrate that in HCC, hepatic Trem-2 levels correlated 
with HSC activation in the tumour microenvironment and that 
Hgf is suppressed by TREM-2 during regeneration.
Nonetheless, the protective effects of TREM-2 were apparent 
at many levels including inflammation, ROS and growth factor 
production. In this regard, ROS are described to modulate Wnt, 
growth factor signalling and inflammation.67 68 Administration of 
antioxidant diets to mice inhibits DEN- mediated hepatocarcino-
genesis by reducing ROS and ROS- mediated DNA damage.30 33 
Our data demonstrating that the antioxidant BHA is able to 
almost completely block DEN- induced hepatocarcinogenesis in 
both genotypes is consistent with these reports, and additionally 
connects the suppressive effects of TREM-2 on ROS to damp-
ened hepatocyte proliferation and damage. While, admittedly we 
cannot pinpoint what is the most important contributing effect 
of TREM-2 to HCC protection, we provide solid evidence that 
TREM-2 exerts multiple biological effects that likely together 
contribute to decreased HCC pathogenesis. Our work is also in 
line with previous observations indicating that the proinflam-
matory receptor TREM-1, which exerts opposing functions to 
TREM-2,5 is detrimental in HCC.31 Despite this, we are hesi-
tant to conceptually label TREM-2 as a ‘tumour suppressor’ in 
HCC.56 In this regard, we and others have shown that TREM-2 
is not expressed in mouse hepatocytes and here we observe 
no TREM-2 expression on transformed human hepatocytes, 
suggesting insignificant effects of hepatocyte TREM-2 deficiency 
to the murine DEN model.16 69 Furthermore, to our knowledge, 
unlike classic tumour suppressor genes such as p53,70 there are 
no published genome wide association studies supporting that 
rare TREM-2 variants are associated with HCC risk. Rather, 
such studies have conclusively demonstrated links with Alzhei-
mer’s disease.10
In summary, all these data indicate that TREM-2 plays a 
critical role during hepatocarcinogenesis, negatively regulating 
liver inflammation, oxidative stress and Wnt ligand secretion 
(figure 9). In this context, TREM-2 prevents hepatocyte prolif-
eration and damage, and consequently HCC development and 
growth. Thus, by exerting suppressive effects on diverse HCC 
promoting processes, non- parenchymal TREM-2 represents a 
central hub that is relevant and critical for HCC pathogenesis. 
In this regard, the future determination of the TREM-2 ligands 
will open new avenues for therapeutic interventions. Moreover, 
our results suggest an importance for investigating TREM-2 
agonists. Although cell- type specific TREM-2 agonism is likely 
challenging, hepatic TREM-2 agonism would presumably atten-
uate inflammation and oxidative stress in both non- parenchymal 
hepatic stromal cells and tumour infiltrating monocyte- derived 
macrophages. Thereby, although, it may prevent hepatocyte 
damage, proliferation and impact HCC tumour burden in a 
multifactorial manner, it might be associated with unwarranted 
effects on fibrosis.
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